Have a feature idea you'd love to see implemented?
Let us know!
SRDX Surmodics Inc
Price (delayed)
$39.33
Market cap
$563.44M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.82
Enterprise value
$556.88M
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic (IVD) immunoassay tests and microarrays. Surmodics
Highlights
SRDX's quick ratio is up by 11% year-on-year
The gross profit is down by 14% year-on-year but it is up by 4.1% since the previous quarter
SRDX's revenue is down by 4.9% YoY but it is up by 4.4% QoQ
SRDX's gross margin is down by 9% year-on-year
Key stats
What are the main financial stats of SRDX
Market
Valuations
Earnings
Shares outstanding
14.33M
Market cap
$563.44M
Enterprise value
$556.88M
Price to book (P/B)
4.72
Price to sales (P/S)
4.42
EV/EBIT
N/A
EV/EBITDA
100.67
EV/Sales
4.42
Revenue
$126.08M
EBIT
-$3.97M
EBITDA
$5.53M
Free cash flow
-$3.24M
Per share
Balance sheet
Liquidity
EPS
-$0.82
Free cash flow per share
-$0.23
Book value per share
$8.33
Revenue per share
$8.91
TBVPS
$7.8
Total assets
$178.56M
Total liabilities
$59.67M
Debt
$29.55M
Equity
$118.9M
Working capital
$60.76M
Debt to equity
0.25
Current ratio
3.96
Quick ratio
2.6
Net debt/EBITDA
-1.19
Margins
Efficiency
Dividend
EBITDA margin
4.4%
Gross margin
73.8%
Net margin
-9.2%
Operating margin
-4.5%
Return on assets
-6.4%
Return on equity
-9.6%
Return on invested capital
-4.3%
Return on capital employed
-2.5%
Return on sales
-3.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SRDX stock price
How has the Surmodics stock price performed over time
Intraday
0.36%
1 week
1.58%
1 month
2.74%
1 year
15.13%
YTD
8.2%
QTD
1.42%
Financial performance
How have Surmodics's revenue and profit performed over time
Revenue
$126.08M
Gross profit
$93.05M
Operating income
-$5.65M
Net income
-$11.54M
Gross margin
73.8%
Net margin
-9.2%
SRDX's operating margin is up by 18% since the previous quarter
The operating income has grown by 15% from the previous quarter
The gross profit is down by 14% year-on-year but it is up by 4.1% since the previous quarter
SRDX's gross margin is down by 9% year-on-year
Growth
What is Surmodics's growth rate over time
Valuation
What is Surmodics stock price valuation
P/E
N/A
P/B
4.72
P/S
4.42
EV/EBIT
N/A
EV/EBITDA
100.67
EV/Sales
4.42
The stock's price to book (P/B) is 10% more than its last 4 quarters average of 4.3 and 7% more than its 5-year quarterly average of 4.4
SRDX's P/S is 13% below its 5-year quarterly average of 5.1 but 11% above its last 4 quarters average of 4.0
SRDX's revenue is down by 4.9% YoY but it is up by 4.4% QoQ
Efficiency
How efficient is Surmodics business performance
The company's return on sales has shrunk by 169% YoY but it rose by 33% QoQ
The ROIC has plunged by 157% YoY but it has grown by 30% from the previous quarter
Dividends
What is SRDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SRDX.
Financial health
How did Surmodics financials performed over time
The total assets is 199% more than the total liabilities
SRDX's quick ratio is up by 11% year-on-year
The current ratio has grown by 9% YoY
The debt is 75% smaller than the equity
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.